Claims for Patent: 8,834,920

Summary for Patent: 8,834,920

Title:	Liposome composition for targeting egfr receptor
Abstract:	Short oligopeptides are provide which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided.
Inventor(s):	Huang; Ken Shi Kun (Castro Valley, CA), Zhang; Weiming (San Francisco, CA), Zhang; Guoyang (San Jose, CA), Nicol; Francois (Carlsbad, CA), Huang; Anthony (Saratoga, CA)
Assignee:	Alza Corporation (Mountain View, CA)
Application Number:	12/513,383
Patent Claims:	1. A composition, comprising liposomes comprised of (i) vesicle-forming lipids; (ii) a lipopolymer; (iii) a conjugate comprised of a hydrophobic moiety, a hydrophilic polymer, and a peptide which exhibits one or more properties selected from a) competitive binding with known EGFR ligands, EGF and TGF-.alpha.; b) ability to compete with the neutralizing monoclonal antibody cetuximab for binding to EGFR; c) binding to a non-ligand binding domain on EGFR; and d) ability to bind to extracellular domain of EGFR in the presence of EGF; and (iv) an entrapped drug, wherein the peptide has the amino acid sequence selected from SEQ ID NOs 6, 7, 8, 9 or 55. 2. A composition according to claim 1, the peptide comprising the sequence LCXX.PHI..PHI.HPLC, where .PHI. is F or Y (SEQ ID NO: 9). 3. A composition according to claim 1, wherein the peptide comprises at least one sequence selected from SEQ ID NOs: 6, 7, or 8. 4. A composition according to claim 1, the peptide comprising the sequence DPCTWEVWGRECLQ (SEQ. ID. No.55). 5. A composition according to claim 1, the conjugate comprising polyethylene glycol having a molecular weight of between 750-5000 Daltons. 6. A composition according to claim 1, the vesicle-forming lipid comprising at least one rigid vesicle-forming lipid. 7. A composition according to claim 1, the vesicle-forming lipid comprising a rigid vesicle-forming lipid. 8. A composition according to claim 1, the vesicle-forming lipid comprising hydrogenated soy phosphatidyl choline. 9. A composition according to claim 1, the vesicle-forming lipid comprising cholesterol. 10. A composition according to claim 1, the lipopolymer comprising a hydrophobic moiety and polyethylene glycol having a molecular weight of between 750-5000 Daltons. 11. A composition according to claim 1, the hydrophobic moiety comprising distearoyl phosphatidylethanolamine. 12. A composition according to claim 1, wherein composition comprises the peptide in a ratio of 40-240 peptide per liposome. 13. A composition according to claim 1, wherein the entrapped drug is doxorubicin. 14. A method of treating, a hyperproliferative cell disease associated with cells that express EGFR in a subject in need thereof, said method comprising administering to said subject the composition of claim 1. 15. A method according to claim 14, wherein the hyperproliferative cell disease is cancer. 16. A method according to claim 15, wherein the cancer is selected from the group consisting of a cancer of gastrointestinal tract, breast cancer, lung cancer, renal cancer, and cutaneous cancers.

Details for Patent 8,834,920

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26